: {3 i& P4 T% p4 T
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: 2 G. N5 \, u( ^# y& FEverolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.4 j9 n, o4 D6 z" G, Y, b http://www.ncbi.nlm.nih.gov/pubmed/229681845 m7 @( x4 w! }! v D! h
5 T# b2 ~& ]1 ^1 U( a3 Y( b
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制) Y5 I$ t4 g( p. | http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx